检索结果-南通市图书馆

P11 The Other Form of PBL： Small Group Discussion in Pharmacology Teaching

中国药理通讯 2006年第2期23卷 20-21页

作者： lian-jun guo rong ma fang wang jian-guo chen Department of Pharmacology Tongji Medical College Huazhong University of Science and Technology. Wuhan 430030 China

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Other Form of PBL:Small Group Discussion in Pharmacology Teaching

The Other Form of PBL:Small Group Discussion in Pharmacology...

引用

Satellite Meeting on Pharmacological Teaching & The 15th World Congress of Pharmacology

作者： lian-jun guo rong ma fang wang and jian-guo chen Department of Pharmacology Tongji Medical College Huazhong University of Science and Technology. Wuhan 430030 China

＜正＞Problem-based learning （ PBL） is now an established method in undergraduate medical education that aims to develop reasoning skills based on clinical problems. PBL is an

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Optimal Waist Circumference Cut-off values for Identifying Metabolic Risk Factors in Middle-aged and Elderly Subjects in Shandong Province of China

引用

Biomedical and Environmental Sciences 2014年第5期27卷 353-359页

作者： HOU Xin guo wang Chuan ma Ze Qiang YANG Wei fang wang Ji Xiang LI cheng Qiao wang Yu lian LIU Shu Min Hu Xiu Ping ZHANG Xiu Ping jianG Mei wang Wei Qing NING Guang ZHENG Hui Zhen ma Ai Xia SUN Yu SONG jun LIN Peng lianG Kai LIU Fu Qiang LI Wen Juan XIAO Juan GONG Lei wang Mei jian LIU Ji Dong YAN Fei YANG jun Peng wang Ling Shu TIAN Meng ZHAO Ru Xing jianG Ling chen Li Department of Endocrinology Qilu Hospital and Institute of Endocrinology and Metabolism Shandong University China National Heavy Duty Truck Group Corporation Hospital Jining Lukang Hospital Department of Endocrinology Jining Second People's Hospital Shantui Community Health Center Department of Endocrine and Metabolic Diseases Ruijin HospitalShanghai Jiaotong University Medical School

Objective To study the optimal waist circumference （WC） cut-off values for identifying metabolic risk factors in middle-aged and elderly subjects in Shandong Province of China. Methods A total of 2 873 men and 5 559 women were included in this cross-sectional study. Metabolic syndrome （MetS） was diagnosed according to the definition of Chinese Diabetes Society in 2004. The relation between WC and MetS was analyzed by multivariate logistic regression analysis. The optimal WC cut-off values were identified using the area under the ROC curve and the different diagnostic criteria for central obesity were compared. Results The WC was the risk factor for MetS independent of BMI, blood glucose, blood lipid, and blood pressure. The optimal WC cut-off value was 83.8 cm and 91.1 cm for identifying MetS in women and men, respectively. Compared with 80 cm and 85 cm for women and men, 85 cm and 90 cm had a higher Youden index for identifying all metabolic risk factors and MetS in women and men. Conclusion The appropriate WC cut-off value is 85 cm and 90 cm for identifying central obesity and MetS in women and men in Shandong Province of China.

关键词： Waist circumference Metabolic syndrome Central obesity

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

SAPT:a synchrotron-based proton therapy facility in Shanghai

引用

Nuclear Science and Techniques 2023年第10期34卷 36-46页

作者： man-Zhou Zhang De-Ming Li Li-Ren Shen Hai-rong Zhang Zhi-Ling chen Han-Wen Du Ming Gu Rui Li De-Kang Liu Yue-Hu Pu jun-Feng Yu jian-Feng chen Chu chen Chun-Long guo Hao guo Ge-Yang jiang Zhi-Qiang jiang Lin Jin Wen-Jing Li Xiu-fang Li Ye Lin Ming Liu Yong-Hao Liu Ya-Juan Liu Ming Lv Qing-Ru Mi lian-Hua Ouyang Wei-guo Shi Hang Shu Qi-Sheng Tang Kun wang Zhi-Shan wang jun Wu Xiao-Bing Wu Jia-Qiang Xu Wen-Zhen Xu Chong-Xian Yin cheng Yu Ren-Xian Yuan Qi-Bing Yuan Hai-Qun Zhang Miao Zhang Wen-Zhi Zhang Li-Ying Zhao Wei-Min Zhou Shou-Xian fang Xi-Dong Sun Zhen-Tang Zhao Shanghai Institute of Applied Physics Chinese Academy of SciencesShanghai 201800China Shanghai Advanced Research Institute Chinese Academy of SciencesShanghai 201204China APACTRON Particle Equipment Co. Ltd.Shanghai 201815China The Institute of High Energy Physics Chinese Academy of SciencesBeijing 100049China

Because of its excellent dose distribution,proton therapy is becoming increasingly popular in the medical application of cancer treatment.A synchrotron-based proton therapy facility was designed and constructed in *** synchrotron,beam delivery system,and other technical systems were commissioned and reached their expected *** a clinical trial of 47 patients was finished,the proton therapy facility obtained a registration certificate from the National Medical Products *** characteristics of the accelerator and treatment systems are described in this article.

关键词： Proton therapy Synchrotron Slow extraction Gantry Beam delivery system

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

引用

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang Yue-yi Deng Wei Li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan Lin Zhi-yong guo jun Zhu Jing-ai fang Xu-sheng Liu Li-hua wang rong wang Nian-song wang Xiao-hong cheng Li-qun He Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru jiang Hong-yu chen Wen-hu Liu Hong-li Lin Meng liang Lu ma Ming chen Li-qun Song jian chen Qing Zhu Chang-ying Xing Yun Li Ji-ning Gao rong-shan Li Ying Li Hao Zhang Ying Lu Qiao-ling Zhou jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(P<0.001)greater reduction in urine protein *** with the losartan potassium 100 mg group,the SYKFT plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial

引用

Cancer Communications 2021年第9期41卷 889-903页

作者： Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng wang jianhua Shi Ming Zhou Qian Sun guolei wang Dongji chen Yongqian Shu lianke Liu Zhongliang guo Yong Liu junquan Yang Ke wang Ke Xiao LinWu Tienan Yi Debin Sun mafei Kang Tianjiang ma Yimin mao Jinsheng Shi Tiegang Tang Yan wang Puyuan Xing Dongqing Lv wangjun Liao Zhiguo Luo Bin wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen guo rongyu Liu Zhiwei Lu jianyong Zhang jian fang Changlu Hu Yinghua Ji guolong Liu Hong Lu Dedong Wu junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng jun chen Zhanyu Pan Yiping Zhang Wenjuan lian Bo jiang Bo Qiu guojun Zhang Hua Zhang Yanju chen Yuan chen Hongbing Duan manxiang Li Shengming Liu Lijun ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin wang Can Wu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021P.R.China Department of Oncology Yibin Second People’s HospitalYibinSichuan 644000P.R.China Department of Oncology Liuzhou People’s HospitalLiuzhouGuangxi 545006P.R.China Department of Thoracic Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Oncology Department the First Affiliated Hospital of Bengbu Medical CollegeBengbuAnhui 233030P.R.China Department of Oncology the First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouGuangdong 510030P.R.China Department of Internal medicine Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Thoracic Surgery the Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510095P.R.China Department of Internal Medicine-Oncology/Department of thoracic oncology Henan Chest HospitalZhengzhouHenan 450003P.R.China The Second Department of Radiotherapy Wuwei Cancer Hospital of Gansu ProvinceWuweiGansu 730000P.R.China Department of Oncology the People’s Hospital of Jiangsu ProvinceNanjingJiangsu 210000P.R.China Respiratory Medicine Department Shanghai East HospitalShanghai 200120P.R.China The Second Department of Internal Medicine-Oncology Xuzhou Central HospitalXuzhouJiangsu 221009P.R.China Oncology Department Tangshan People’s HospitalTangshanHebei 063001P.R.China Respiratory Medicine Department West China Hospital of Sichuan UniversityChengduSichuan 610041P.R.China Thoracic Surgery the Second Affiliated Hospital of Shantou University Medical CollegeShantouGuangdong 515051P.R.China Internal Medicine-Oncology Hunan Cancer HospitalChangshaHunan 410013P.R.China Department of Oncology Xiangyang Central HospitalXiangyangHubei 441021P.R.China Respiratory Department Lishui Central HospitalLishuiZ

Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or *** primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and *** study was registered in Clinical ***(NCT03533127).Results:Between December 15^(th),2017,and may 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)*** of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)*** responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,*** stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to may 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY010

关键词： anti-angiogenesis anti-VEGF monoclonal antibody avastin bevacizumab biosimilar nonsmall cell lung cancer LY01008 vascular endothelial growth factor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

引用

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： jun Liu Dan-Dan Li Wei Dong Yu-Qi Liu Yang Wu Da-Xuan Tang Fu-Chun Zhang Meng Qiu Qi Hua Jing-Yu He jun Li Bai Du Ting-Hai Du Lin-Lin Niu Xue-jun jiang Bo Cui jiang-Bin chen Yang-Gan wang Hai-rong wang Qin Yu Jing He Yi-Lin mao Xiao-fang Bin Yue Deng Yu-Dan Tian Qing-Hua Han Da-Jin Liu Li-Qin Duan Ming-jun Zhao Cui-Ying Zhang Hai-Ying Dai Ze-Hua Li Ying Xiao You-Zhi Hu Xiao-Yu Huang Kun Xing Xin jiang Chao-Feng Liu Jing An Feng-Chun Li Tao Tao Jin-Fa jiang Ying Yang Yao-rong Dong Lei Zhang Guang Fu Ying Li Shu-Wei Huang Li-Ping Dou Lan-jun Sun Ying-Qiang Zhao Jie Li Yun Xia jun Liu Fan Liu Wen-Jin He Ying Li jian-Cong Tan Yang Lin Ya-Bin Zhou jian-Fei Yang guo-Qing ma Hui-jun chen He-Ping Liu Zong-Wu Liu jian-Xiong Liu Xiao-Jia Luo Xiao-Hong Bin Ya-Nan Yu Hai-Xia Dang Bing Li Fei Teng wang-Min Qiao Xiao-Long Zhu Bing-Wei chen Qi-Guang chen Chun-Ti Shen Yong-Yan wang Yun-Dai chen Zhong wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated Zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Diagnosis and Treatment of Cholangiocarcinoma: A Consensus from Surgical Specialists of China

引用

Journal of Huazhong University of Science and Technology(Medical Sciences) 2014年第4期34卷 469-475页

作者： jian-qiang Cai Shou-wang Cai Wen-ming Cong Min-shan chen Ping chen Xiao-ping chen Yan-ling chen Yi-fa chen Chao-liu Dai Qiang Huang Zhi-yong Huang Bo jiang Bin jiang Ke-wei jiang Bo Li Zong-fangLi Li-jian liang Bin Liu Hui-chun Liu lian-xin Liu Qing-guang Liu rong Liu Ying-bin Liu jian-guo Lu Shi-chun Lu Yi Lu Yi-lei mao Bin Mei jun Niu Bao-gang Peng Xiao Qin Yu-dong Qiu Guang-yi wang Yao-don wangg Zhi-ming wang Ren-hua Wan Ya-fu Wu Bao-cai Xing Feng Xia Ge-liang Xu Jia-mei Yang Xiao-fang Yu Yong Zeng Yong-yi Zeng Bi-xiang Zhang Bin-hao Zhang Qi-yu Zhang Shui-jun Zhang Wan-guang Zhang Yong-jie Zhang Zhi-wei Zhang Dong Zhou Wei-ping Zhou Cancer Institute and Hospital Chinese Academy of Medical Sciences Chinese PLA General Hospital Eastern Hepatobiliary Surgery Hospital of Second Military Medical University Sun Yat-sen University Cancer Center Daping Hospital of Third Military Medical University Tongji Hospital Tongji Medical CollegeHuazhong University of Science and Technology Fujian Medical University Union Hospital Shengjing Hospital of China Medical University Anhui Provincial Hospital Hunan Provincial People’s Hospital Taihe Hospital Affiliated to Hubei University of Medicine Peking University People’s Hospital West China Hospital Sichuan University The Second Affiliated Hospital of Xi’an Jiao Tong University The First Affiliated Hospital Sun Yat-sen University First Affiliated Hospital of Kunming Medical University The First Affiliated Hospital of Bengbu Medical College The First Affiliated Hospital of Harbin Medical University The First Affiliated Hospital of Xi’an Jiao Tong University Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Tangdu Hospital of Fourth Military Medical University Peking Union Medical College Hospital Qilu Hospital of Shandong University The First Affiliated Hospital of Guangxi Medical University Nanjing Drum Tower Hospital The First Affiliated Hospital of Jilin University Fujian Provincial Hospital Xiangya Hospital of Central South University The First Affiliated Hospital of Nanchang University Beijing Cancer Hospital Southwest Hospital of Third Military Medical University Shenzhen People’s Hospital The First Affiliated Hospital of Fujian Medical University The First Affiliated Hospital of Wenzhou Medical University The First Affiliated Hospital of Zhengzhou University Fujian Provincial Cancer Hospital

Cholangiocarcinoma refers to malignant tumors that develop in epithelial lining of biliary system, and it is divided into two categories according to tumor location, intrahepatic cholangiocarcinoma （ICC） and extrahepatic cholangiocarcinoma （ECC）. ICC occurs from the epithelial cells of the intrahepatic bile duct, its branches and interlobular biliary tree; and ECC is divided into hilar cholangiocarcinoma and distal cholangiocarcinoma by the circumscription at the confluence of cystic duct and the common hepatic duct.

关键词： A Consensus from Surgical Specialists of China Diagnosis and Treatment of Cholangiocarcinoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

International consensus on natural orifice specimen extraction surgery(NOSES)for gastric cancer(2019)

引用

Gastroenterology Report 2020年第1期8卷 5-10,I0001页

作者： Xu Guan Zheng Liu Amjad Parvaiz Antonio Longo Avanish Saklani Ali AShafik jian-Chun Cai Charles Ternent Lin chen Cuneyt Kayaalp Fatih Sumer Fernanda Nogueira Feng Gao fang-Hai Han Qing-Si He Ho-Kyung Chun Chang-Ming Huang Hai-Yang Huang Rui Huang Zhi-Wei jiang Jim S Khan Joaquim manuel da Costa Pereira JosephWNunoo-Mensah jung Tack Son liang Kang Keisuke Uehara Ping Lan Le-Ping Li Han liang Bing-rong Liu Juan Liu Dan ma Ming-Yin Shen Mohammad Rashidul Islam Narimantas Evaldas Samalavicius Kai Pan Petr Tsarkov Xin-Yu Qin Ricardo Escalante Sergey Efetov Seung Kyu Jeong Suk-Hwan Lee Dong-Hui Sun Li Sun Tatiana Garmanova Yan-Tao Tian Gui-Yu wang guo-jun wang guo-rong wang Xiao-Qiang wang William Tzu-liang chen Woo Yong Lee Su Yan Zu-Li Yang Gang Yu Pei-Wu Yu Dan Zhao Yun-Shi Zhong jian-Ping wang Xi-Shan wang The International Alliance of NOSES Department of Colorectal Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingP.R.China Poole Hospital NHS Trust PooleUK European Center of Coloproctology and Pelvic Diseases-Multimedica Hospital MilanItaly Department of GI Surgical Oncology Tata Memorial HospitalMumbaiIndia Department of Colorectal Surgery Cairo UniversityCairoEgypt Department of Gastrointestinal Surgery Zhongshan Hospital of Xiamen UniversityXiamenFujianP.R.China Section of Colon and Rectal Surgery Creighton University School of MedicineOmahaNEUSA Department of General Surgery Chinese People’s Liberation Army General HospitalBeijingP.R.China Department of Gastrointestinal Surgery Inonu UniversityMalatyaTurkey Department of Surgery Hospital de BragaBragaPortugal Department of Colorectal Cancer Surgery the Second Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangP.R.China Department of Gastroenterological Surgery Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdongP.R.China Department of General Surgery Shandong University Qilu HospitalJinanShandongP.R.China Department of Surgery Kangbuk Samsung HospitalSungkyunkwan University School of MedicineSeoulSouth Korea Department of Gastric Surgery Fujian Medical University Union HospitalFuzhouFujianP.R.China Department of General Surgery Jiangsu Province Hospital of Traditional Chinese MedicineNanjingJiangsuP.R.China Department of Colorectal Surgery PortsmouthHospitals NHSTrustQueen Alexandra HospitalPortsmouthUK King’s College Hospital LondonUK Department of Colorectal Surgery The Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhouGuangdongP.R.China Division of Surgical Oncology Department of SurgeryNagoya University School of MedicineNagoyaJapan Department of Gastrointestinal Surgery Shandong Provincial Hospital Affiliated to Shandong UniversityJinanShandongP.R.China Department of Gastric Cancer

At present,natural orifice specimen extraction surgery(NOSES)has attracted more and more attention worldwide,because of its great advantages including minimal cutaneous trauma and post-operative pain,fast post-operative recovery,short hospital stay,and positive psychological ***,NOSES for the treatment of gastric cancer(GC)is still in its infancy,and there is great potential to improve its theoretical system and clinical ***,several key points including oncological outcomes,bacteriological concerns,indication selection,and standardized surgical procedures are raised with this innovative ***,it is necessary to achieve an international consensus to regulate the implementation of GC-NOSES,which is of great significance for healthy and orderly development of NOSES worldwide.

关键词： gastric cancer natural orifice specimen extraction surgery transanal specimen extraction transvaginal specimen extraction transoral specimen extraction consensus

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Consensus on the digestive endoscopic tunnel technique

引用

World Journal of Gastroenterology 2019年第7期25卷 744-776页

作者： Ning-Li Chai Hui-Kai Li En-Qiang Linghu Zhao-Shen Li Shu-Tian Zhang Yu Bao Wei-Gang chen Philip WY Chiu Tong Dang Wei Gong Shu-Tang Han jian-Yu Hao Shui-Xiang He Bing Hu1 Bing Hu2 Xiao-jun Huang Yong-Hui Huang Zhen-Dong Jin Mouen A Khashab James Lau Peng Li Rui Li De-liang Liu Hai-Feng Liu jun Liu Xiao-Gang Liu Zhi-guo Liu Ying-Cai ma Gui-Yong Peng Long rong Wei-Hong Sha Pateek Sharma jian-Qiu Sheng Shui-Sheng Shi Dong Wan Seo Si-Yu Sun Gui-Qi wang Wen wang Qi Wu Hong Xu Mei-Dong Xu Ai-Ming Yang fang Yao Hong-Gang Yu Ping-Hong Zhou Bin Zhang Xiao-Feng Zhang Ya-Qi Zhai Department of Gastroenterology and Hepatology Chinese PLA General HospitalBeijing 100853China Department of Gastroenterology Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Gastroenterology the First Affiliated Hospital of Xi’an Jiao Tong UniversityXi’an 710000Shaanxi ProvinceChina Department of Gastroenterology West China HospitalSichuan UniversityChengdu 610041Sichuan ProvinceChina Department of Endoscopy Eastern Hepatobiliary Surgical Hospital Affiliated to Naval Medical UniversityShanghai 200438China Department of Gastroenterology the Second Hospital of Lanzhou UniversityLanzhou 730030Gansu ProvinceChina Department of Gastroenterology Peking University Third HospitalBeijing 100191China Division of Gastroenterology and Hepatology the Johns Hopkins University School of MedicineBaltimoreMD 21218United States Department of Gastrointestinal Endoscopy Prince of Wales Hospitalthe Chinese University of Hong KongHong KongChina Department of Gastroenterology the First Affiliated Hospital of Soochow UniversitySuzhou 215006Jiangsu ProvinceChina Department of Gastroenterology Second Xiangya Hospital of Central South UniversityChangsha 410000Hunan ProvinceChina Department of Gastroenterology Changhai HospitalNaval Medical UniversityShanghai 200433China Department of Gastroenterology General Hospital of Chinese People’s Armed Police ForcesBeijing 100039China Division of Gastroenterology Union Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022Hubei ProvinceChina Department of Gastroenterology Sichuan Provincial People’s HospitalChengdu 610072Sichuan ProvinceChina Department of Gastroenterology Xijing HospitalAir Force Medical UniversityXi’an 710032Shaanxi ProvinceChina Department of Digestion Qinghai Provincial People’s HospitalXining 810007Qinghai ProvinceChina Department of Gastroenterology Southwest HospitalArmy Medical UniversityChongqing 400038China Department of Gastroenterology Peking Univ

With the digestive endoscopic tunnel technique(DETT), many diseases that previously would have been treated by surgery are now endoscopically curable by establishing a submucosal tunnel between the mucosa and muscularis propria(MP). Through the tunnel, endoscopic diagnosis or treatment is performed for lesions in the mucosa, in the MP, and even outside the gastrointestinal(GI) *** present, the tunnel technique application range covers the following:(1)Treatment of lesions originating from the mucosal layer, e.g., endoscopic submucosal tunnel dissection for oesophageal large or circular early-stage cancer or precancerosis;(2) treatment of lesions from the MP layer, per-oral endoscopic myotomy, submucosal tunnelling endoscopic resection, etc.; and(3) diagnosis and treatment of lesions outside the GI tract, such as resection of lymph nodes and benign tumour excision in the mediastinum or abdominal cavity. With the increasing number of DETTs performed worldwide, endoscopic tunnel therapeutics, which is based on DETT, has been gradually developed and optimized. However, there is not yet an expert consensus on DETT to regulate its indications, contraindications, surgical procedure, and postoperative *** International DETT Alliance signed up this consensus to standardize the procedures of DETT. In this consensus, we describe the definition, mechanism,and significance of DETT, prevention of infection and concepts of DETTassociated complications, methods to establish a submucosal tunnel, and application of DETT for lesions in the mucosa, in the MP and outside the GI tract(indications and contraindications, procedures, pre-and postoperative treatments, effectiveness, complications and treatments, and a comparison between DETT and other operations).

关键词： Digestive endoscopic tunnel technique Endoscopic submucosal tunnel dissection Per-oral endoscopic myotomy Submucosal tunnelling endoscopic resection Gastrointestinal tract

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：